血液疾患に合併した発熱性好中球減少症に対するmeropenem 1g1日3回投与の臨床的有用性

• Material Type: 文書・図像類
• Title: 血液疾患に合併した発熱性好中球減少症に対するmeropenem 1g1日3回投与の臨床的有用性
• Author/Editor: 池ヶ谷, 諭史; 岩崎, 博道; 李, 心; 高井, 美穂子; 細野, 奈穂子; 岸, 愼治; 山内, 高弘; 吉田, 明; 浦崎, 芳正; 上田, 孝典
• Author Heading: 池ヶ谷, 諭史; 岩崎, 博道; 李, 心; 高井, 美穂子; 細野, 奈穂子; 岸, 愼治; 山内, 高弘; 吉田, 明; 浦崎, 芳正; 上田, 孝典
• Publication Date: 2012-09
• Publication Date (W3CDTF): 2012-09
• Periodical title: 日本化学療法学会雑誌
• No. or year of volume/issue: 60 5
• Volume: 60
• Issue: 5
• Pages: 549-552
• Text Language Code: jpn
• Subject Heading: febrile neutropenia; meropenem; empiric therapy
• Target Audience: 一般
• Note (General): BACKGROUND: Febrile neutropenia (FN) is a very important cause of mortality in patients receiving intensive chemotherapy. In 2010 meropenem (MEPM) 3g per day was approved for the treatment of FN in Japan, however, there are not enough reports about 3g usage of MEPM in Japanese patients yet. OBJECTIVE: This study assessed the clinical efficacy and safety of MEPM 1g three times a day as empirical monotherapy for FN in hematological patients. METHODS: This is the retrospective cohort study involved inpatients at Fukui university hospital. Fifty-six patients received 3g MEPM from January 2010 to January 2011. The mean age was 64.2. The underlying diseases were acute leukemia in 33 cases, malignant lymphoma in 15 and myelodysplastic syndrome in 8. RESULTS: The response rate was 80% (excellent response: 62%, good response: 18%, minor response: 16%, no response: 4%). The febrile duration was average 4.18 days. Treatment did not need to be discontinued or interrupted due to adverse events in any of the patients. CONCLUSIONS: This study suggests that MEPM 1g three times per day is useful and tolerable therapy in Japanese FN patients.
• Access Restrictions: 限定公開
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 福井大学 : 福井大学学術機関リポジトリ